The type 1 diabetes clinic nurse’s communication challenge
The type 1 diabetes clinic nurse faces a communication environment shaped by a systematic mismatch: the name “diabetes” implies a single condition with a spectrum of severity, but the clinical reality is that type 1 and type 2 diabetes are mechanistically distinct diseases that share a name, a complication profile, and a diagnostic criterion but differ in cause, treatment logic, and everything that flows from cause and treatment. This mismatch creates a field of predictable misunderstandings. Families who know someone with type 2 diabetes apply type 2 management logic to a type 1 patient. Patients who have lived with type 1 diabetes for decades encounter their own disease through a framework the condition itself progressively distorts. And clinicians outside diabetes care apply population-level diabetes management guidelines developed primarily in type 2 populations to patients whose disease is a different thing entirely.
The first recurring failure occurs at or near diagnosis, particularly in adults: the patient who presents with modest A1c elevation, no ketoacidosis, and adult age is diagnosed as type 2 diabetes, started on metformin, and treated for months or years before positive autoantibodies and falling C-peptide reveal the true diagnosis of LADA — latent autoimmune diabetes of adults, the adult-onset form of type 1 diabetes. The treatment change that follows — from an oral agent that modifies hepatic glucose metabolism to insulin that replaces the hormone the immune system has destroyed — requires an explanation that begins with why the treatments differ and why the mechanism difference makes them non-interchangeable.
The second recurring failure occurs in routine glycemic monitoring. The A1c target of under 7 percent has been so well communicated to patients with diabetes and their families that it functions as the single proxy metric for “controlled.” But A1c is a mathematical average, and mathematical averages conceal variance. A patient whose CGM shows half her day above 250 and a tenth of her day below 70 can have the same A1c as a patient whose glucose never leaves the target range. The treatment logic that follows from each situation is entirely different, and explaining why a near-target A1c does not mean adequate glycemic control requires clarifying what A1c measures and what it structurally cannot capture.
The third recurring failure occurs in long-standing type 1 diabetes: the progressive loss of hypoglycemia warning symptoms. Normal physiology provides an early-warning system for falling blood glucose: adrenergic activation produces symptoms that alert the patient before cognitive impairment occurs. Repeated hypoglycemia degrades this system, shifting the warning threshold downward through a process called hypoglycemia-associated autonomic failure. When the system fails, the patient no longer feels the warning, and the first sign of dangerous hypoglycemia may be cognitive impairment severe enough to prevent self-treatment. The patient — and their family — may interpret the absence of symptoms as reassurance that the low glucose is tolerable. It is not. It is the disappearance of the alarm.
Three conversations that recur across the type 1 diabetes clinic:
Scenario 1: Rafael Castillo-Mendoza — 42, HVAC technician from San Antonio, Texas
Rafael Castillo-Mendoza had been sweating through commercial HVAC service calls in San Antonio’s summer heat for eighteen years, and he was not someone who went to the doctor without a concrete reason. The concrete reason, eight months ago, had been a corporate physical required for a new commercial contract — a physical that had found an A1c of 10.3 percent and a fasting glucose of 248 mg per deciliter. The primary care physician had diagnosed type 2 diabetes. He was forty-one, moderately overweight at a BMI of 29.1, with a family history of type 2 diabetes on his mother’s side. The clinical picture fit. He had been started on metformin 1000 mg twice daily and counseled on diet and exercise. He had been faithful to both: he had cut refined carbohydrates, walked forty minutes every morning, lost eleven pounds in six months. And his A1c had improved only modestly, to 9.1 percent at the three-month check and 8.6 percent at six months. His primary care physician had increased the metformin to maximum dose and added a second agent, which had produced gastrointestinal side effects severe enough that he had discontinued it within three weeks.
His primary care physician referred him to the diabetes clinic for medication optimization. The diabetes nurse practitioner who reviewed his labs noted something his primary care workup had not included: she ordered GAD-65 (glutamic acid decarboxylase 65) antibodies and a fasting C-peptide. The GAD-65 returned positive at 3.2 IU/mL. The C-peptide was 0.4 ng/mL — low for a patient with a glucose of 226 mg per deciliter at the time of the draw. This was not type 2 diabetes. This was LADA: Latent Autoimmune Diabetes of Adults.
The nurse practitioner started insulin: basal glargine plus mealtime lispro. The referring PCP updated the diagnosis in the chart. When Rafael came to see the diabetes education nurse, Esperanza Villanueva-Torres, for his insulin education appointment, he brought his wife Cecilia, who worked as a dental receptionist at a practice near their house in the Alamo Ranch neighborhood. Cecilia was attentive and organized. She had been helping Rafael track his meals and glucose readings on a shared phone app. She had a question before Esperanza had finished her introduction.
“No entiendo el cambio,” Cecilia said. “El médico de cabecera le dijo que tenía diabetes tipo 2. Ahora le están cambiando el medicamento a insulina como si tuviera una enfermedad completamente diferente. ¿Cambió el diagnóstico o cambió el tratamiento? ¿Y si era diabetes tipo 2 antes, por qué la metformina no funcionó?” (I do not understand the change. The primary care physician told him he had type 2 diabetes. Now they are changing his medication to insulin as if he had a completely different disease. Did the diagnosis change or did the treatment? And if it was type 2 diabetes before, why did metformin not work?)
Esperanza had heard variants of this question many times at the transition from an oral agent to insulin. “Ambas cosas,” she said. “El diagnóstico cambió porque los nuevos análisis muestran que la diabetes de Rafael no es tipo 2 — es un tipo de diabetes tipo 1 que comienza en adultos y que al principio puede verse igual que la tipo 2. Y el tratamiento cambió porque el mecanismo de la enfermedad es diferente y la metformina no puede hacer lo que la insulina hace.” (Both things. The diagnosis changed because the new tests show that Rafael’s diabetes is not type 2 — it is a type of type 1 diabetes that begins in adults and at first can look the same as type 2. And the treatment changed because the disease mechanism is different and metformin cannot do what insulin does.)
She explained the difference from the mechanism. Type 2 diabetes, she said, was a condition in which the pancreas still produced insulin, but the body’s tissues — the liver, the muscles, the fat cells — did not respond as well to insulin as they should. Think of insulin as a key and the tissue cells as locks: in type 2 diabetes, the locks are stiff. The pancreas compensates by making more keys. Metformin helped by telling the liver — one of the tissues that was producing too much glucose on its own — to slow down. The reason metformin could tell the liver to slow down was that insulin was still present to suppress the glucagon signal that told the liver to produce glucose in the first place. Metformin amplified a process that depended on insulin being there.
Type 1 diabetes, she continued, was a different disease entirely. In type 1 diabetes, the immune system — the system that normally attacked viruses and bacteria — misidentified the insulin-producing beta cells of the pancreas as foreign and destroyed them. She used the Spanish term: “los linfocitos T del sistema inmune atacan y destruyen las células beta que hacen la insulina.” In LADA, this destruction happened slowly — over months or years — which was why adults with LADA could appear to have type 2 diabetes at first. Rafael had still had some functioning beta cells eight months ago; the metformin might have had a modest effect. But the GAD-65 antibodies — proteins his immune system was producing as part of the attack on his beta cells — were still circulating. The C-peptide, which was a byproduct of insulin production released from beta cells every time they made insulin, was nearly undetectable. His beta cells were nearly gone.
“Cuando ya no hay suficientes células beta que hagan insulina,” Esperanza said, “la metformina no puede hacer nada porque no tiene nada sobre qué actuar. La metformina le dice al hígado que haga menos glucosa — pero esa instrucción funciona a través de la insulina que todavía queda. Cuando ya no hay insulina propia, no hay señal que la metformina pueda amplificar. Y sin insulina, la glucosa que entra en la sangre después de comer no tiene cómo entrar a las células para ser utilizada.” (When there are no longer enough beta cells to make insulin, metformin cannot do anything because there is nothing for it to act on. Metformin tells the liver to make less glucose — but that instruction works through the insulin that is still present. When there is no more endogenous insulin, there is no signal for metformin to amplify. And without insulin, the glucose that enters the blood after eating has no way to enter the cells to be used.)
Rafael had been quiet through most of this. “¿Entonces tomar metformina para la diabetes tipo 1 avanzada es como…?” he started. (So taking metformin for advanced type 1 diabetes is like…?)
“Como tomar un medicamento para mejorar la respuesta al volante de un coche que no tiene motor,” Esperanza said. (Like taking a medication to improve the response to the steering wheel of a car that has no engine.)
Cecilia exhaled slowly. “Ahora tiene sentido,” she said. “No era que el tratamiento estaba fallando — era que el diagnóstico era incompleto.” (Now it makes sense. It was not that the treatment was failing — it was that the diagnosis was incomplete.)
The insulin education took the rest of the appointment. Rafael was a methodical man — the kind of technician who read service manuals before touching equipment — and he took notes on the timing of basal glargine, the carbohydrate ratio for lispro, the correction factor, the importance of never skipping the basal dose. By the end of the appointment he had his insulin pen in his breast pocket and a follow-up at two weeks.
Scenario 2: Valentina Orozco-Herrera — 31, graphic designer from Miami, Florida
Valentina Orozco-Herrera had been diagnosed with type 1 diabetes at age 25, shortly after a viral illness that her endocrinologist believed may have accelerated an autoimmune process that had been developing for years. She was a graphic designer at a small studio in Wynwood, and she had integrated her diabetes management into her daily life with the same visual attention she brought to her work: she tracked her Dexcom CGM on a phone widget, checked her time-in-range report each Sunday, and had learned to anticipate the glucose spike from a midday cafécito as reliably as a forecast. She was, by the standards of type 1 diabetes management, a skilled and engaged self-manager.
Her A1c at her most recent quarterly visit had come back 7.1 percent. The diabetes team had reviewed her CGM report and wanted to discuss adjustments to her insulin-to-carbohydrate ratio for mornings, which was where most of her above-range time was clustering. Valentina had called her sister Patricia before the appointment and told her about it. Patricia had come with her.
Patricia was an elementary school teacher from Hialeah, careful and protective of her younger sister since their mother had returned to Colombia. She had looked up the A1c target before the appointment. “El objetivo es siete por ciento,” she said to the diabetes education nurse, Isabel Morales-Cruz, as the appointment began. “Valentina tiene 7.1. ¿Para qué cambiar algo que está casi perfecto? Puede estresar el control innecesariamente.” (The target is 7 percent. Valentina has 7.1. Why change something that is almost perfect? It could unnecessarily stress the management.)
Isabel recognized this conversation. She had it regularly with family members who had learned the A1c target number without learning what the number measured or what it left unmeasured. “La A1c de 7.1 de Valentina está cerca del objetivo,” she said, “y eso es bueno. Pero la A1c mide el promedio de glucosa de los últimos tres meses — y un promedio puede ser aceptable aunque los valores individuales sean muy altos y muy bajos. El sensor de glucosa nos da más información que el promedio, y lo que el sensor muestra en el caso de Valentina necesita atención aunque el promedio sea bueno.” (Valentina’s A1c of 7.1 is close to the target, and that is good. But the A1c measures the average glucose over the past three months — and an average can be acceptable even when the individual values are very high and very low. The glucose sensor gives us more information than the average, and what the sensor shows in Valentina’s case needs attention even though the average is good.)
She pulled up the CGM report on the clinic monitor. She explained the mechanism of A1c first, because Patricia’s certainty about its adequacy as a monitoring metric needed a foundation to rest on before it could be questioned. The A1c, she said, measured how much glucose had attached itself to the hemoglobin inside red blood cells. Red blood cells circulated for about 90 to 120 days. Glucose in the blood attached to hemoglobin continuously throughout the red blood cell’s life, at a rate proportional to how much glucose was in the blood at any given moment. At the end of the red blood cell’s life, the fraction of hemoglobin that had glucose attached — the A1c percentage — reflected the average glucose concentration over those 90 to 120 days.
“El promedio,” Isabel said, “es una cifra que suma todo y lo divide. Si Valentina tuviera glucosa de 300 la mitad del tiempo y de 50 la otra mitad, el promedio matemático de esos valores sería aproximadamente 175. Una glucosa promedio de 175 corresponde a una A1c de aproximadamente 7.5 por ciento. Eso es casi el objetivo. Pero los valores reales — pasar horas a 300 y horas a 50 — no son un buen control. Son un problema grave que el promedio hace invisible.” (The average is a number that adds everything up and divides it. If Valentina had a glucose of 300 half the time and 50 the other half, the mathematical average of those values would be approximately 175. A mean glucose of 175 corresponds to an A1c of approximately 7.5 percent. That is almost the target. But the actual values — spending hours at 300 and hours at 50 — are not good control. They are a serious problem that the average makes invisible.)
She turned to Valentina’s actual CGM report. The numbers were on the screen: time-in-range (70–180 mg/dL) was 52 percent. Time above 180 was 40 percent, of which 22 percent was above 250. Time below 70 was 8 percent. Time below 54 was 2 percent.
“Valentina está dentro del rango objetivo — entre 70 y 180 — el 52 por ciento del tiempo,” Isabel said. “Eso son aproximadamente 12 horas y media al día. El objetivo de las sociedades de diabetes para la diabetes tipo 1 es al menos el 70 por ciento del tiempo dentro del rango — que son aproximadamente 17 horas al día. Valentina está cuatro y media horas al día por debajo de ese objetivo.” (Valentina is within the target range — between 70 and 180 — 52 percent of the time. That is approximately 12 and a half hours per day. The target of the diabetes societies for type 1 diabetes is at least 70 percent of time within range — which is approximately 17 hours per day. Valentina is four and a half hours per day below that target.)
She moved to the specific consequences of what the CGM showed. The 22 percent of time above 250 mg per deciliter was not a benign number. It represented hours per day during which glucose was at a level that, over time, caused the microvascular toxicity that led to diabetic retinopathy in the retinal capillaries, diabetic nephropathy in the glomeruli, and peripheral diabetic neuropathy in the Schwann cells of small-caliber nerve fibers. The A1c of 7.1 averaged those hours in with the in-range hours and produced a number that looked acceptable. The CGM showed they were happening.
“Y el 8 por ciento de tiempo por debajo de 70,” Isabel continued, “son aproximadamente una hora y cincuenta minutos al día en hipoglucemia. Eso no es solo un número en un papel — son casi dos horas al día con glucosa baja que puede causar síntomas, afectar la concentración en el trabajo, en el coche, en la vida. Y el 2 por ciento de tiempo por debajo de 54 — glucosa muy baja, nivel de hipoglucemia severa — son aproximadamente 29 minutos al día.” (And the 8 percent of time below 70 is approximately one hour and fifty minutes per day in hypoglycemia. That is not just a number on paper — it is almost two hours per day with low glucose that can cause symptoms, affect concentration at work, driving, in daily life. And the 2 percent of time below 54 — very low glucose, severe hypoglycemia level — is approximately 29 minutes per day.)
Patricia had been staring at the CGM report on the screen. Her expression had shifted from protective skepticism to something more like alarm. “Pero la A1c…” she started, then stopped. (But the A1c…)
“La A1c es buena para seguir una tendencia a lo largo del tiempo,” Isabel said. “Pero para entender qué está pasando día a día, el sensor de glucosa es la herramienta correcta. Y lo que el sensor dice es que el patrón de Valentina — glucosa alta por la mañana y tendencia a bajar demasiado por las tardes — puede mejorarse con un ajuste pequeño en la dosis de insulina antes del desayuno. No es que algo esté muy mal. Es que el sensor nos muestra un patrón específico que se puede mejorar con un ajuste pequeño, y eso se ve en el sensor aunque no se vea en la A1c.” (The A1c is useful for following a trend over time. But for understanding what is happening day to day, the glucose sensor is the right tool. And what the sensor says is that Valentina’s pattern — high glucose in the morning and a tendency to drop too low in the afternoons — can be improved with a small adjustment in the insulin dose before breakfast. It is not that something is very wrong. It is that the sensor shows a specific pattern that can be improved with a small adjustment, and that is visible on the sensor even though it is not visible in the A1c.)
Valentina had been listening to her sister and the nurse with the quiet attention of someone who had understood this for a while and was waiting for the conversation to land. “Por eso me pidieron el sensor desde el principio,” she said to Patricia. “La A1c te dice cómo estás yendo en promedio. El sensor te dice qué está pasando.” (That is why they asked me for the sensor from the beginning. The A1c tells you how you are doing on average. The sensor tells you what is actually happening.)
Scenario 3: Eduardo Jiménez-Vargas — 58, retired firefighter from El Paso, Texas
Eduardo Jiménez-Vargas had been managing type 1 diabetes for thirty-two years, since his diagnosis at age 26 while working his first year as a firefighter with the El Paso Fire Department. He had managed the disease the way he had managed fire incidents: methodically, without drama, using the systems available. When CGM technology became widely covered by his retiree insurance three years earlier, he had adopted it immediately. He knew his patterns. He knew his insulin sensitivity varied by temperature and shift, and he had learned that in decades of managing his own condition.
What he did not know — what he could not have known from his own experience, because his experience was the problem — was that over the past year he had gradually stopped feeling his low blood sugars. His wife Dolores, a retired bilingual teacher, had noticed it before he had. She had seen him check the CGM when it alarmed, read 61 mg per deciliter, and say he felt fine. She had seen him eat nothing to treat it. She had seen him ignore a 58 the following Tuesday. The CGM alarms had been going off more often, and Eduardo had been dismissing them because he genuinely felt nothing.
Dolores had called the diabetes clinic to report what she was seeing. The diabetes nurse, Carmen Reyes-Castellanos, had reviewed Eduardo’s CGM download before the appointment. The numbers told a story: time below 70 was 14 percent — more than three hours per day. Time below 54 was 4 percent. Three months ago, both had been 3 percent and 0.5 percent. There had been four CGM low alerts in the past two weeks at values below 54 that had not been treated. His A1c was 6.8 percent — technically excellent by population standards, and consistent with the daily hypoglycemia that was driving it down.
At the appointment, Eduardo sat with his characteristic calm and Dolores sat next to him with a list of dates and times she had written in a small notebook. “Le digo que el sensor marca bajo y dice que no siente nada,” Dolores said. “Y como no siente nada, cree que el número no es un problema. Pero a mí me parece que antes sí sentía los bajos y ahora ya no.” (I tell him the sensor shows low and he says he feels nothing. And because he feels nothing, he thinks the number is not a problem. But it seems to me that before he did feel the lows and now he no longer does.)
Carmen addressed Eduardo directly. “Dolores tiene razón en preocuparse,” she said, “y tiene razón en observar el cambio. Que usted no sienta los bajos ahora cuando antes los sentía no significa que los bajos sean menos peligrosos — significa que el sistema de alarma que le avisaba está dejando de funcionar. Y eso, en la diabetes tipo 1 de muchos años, es algo que tenemos que tomar muy en serio.” (Dolores is right to be concerned, and she is right to have noticed the change. That you no longer feel the lows now when before you did feel them does not mean the lows are less dangerous — it means the alarm system that was warning you is starting to fail. And that, in long-standing type 1 diabetes, is something we need to take very seriously.)
She explained the physiology of hypoglycemia warning symptoms. When blood glucose fell below approximately 65 to 70 mg per deciliter, she said, the brain detected the decline and activated the adrenal glands to release adrenaline — the same stress hormone released in a fire incident, she said to Eduardo, using his professional background. Adrenaline produced the symptoms: the trembling, the sweating, the fast heartbeat, the hunger, the anxiety. These symptoms appeared at a glucose level that was low but not yet low enough to significantly impair thinking. They gave the person time to treat — to drink juice, eat glucose tablets, call for help. The warning system arrived before the problem became unmanageable.
“En la diabetes tipo 1 de muchos años,” she continued, “ocurre algo que se llama fracaso autonómico asociado a la hipoglucemia — en inglés se llama HAAF. Cada vez que hay un episodio de glucosa baja, el cerebro se adapta a ese nivel bajo. La próxima vez que la glucosa baja al mismo nivel, el cerebro ya lo reconoce como ‘normal suficiente’ y no activa la alarma de adrenalina. Con el tiempo, el umbral al que se activa la alarma se desplaza hacia abajo — el cuerpo deja de producir los síntomas de aviso a glucosas donde antes sí los producía. El paciente llega a niveles de glucosa bajos donde el cerebro ya no funciona bien sin haber sentido ningún síntoma que le avisara.” (In long-standing type 1 diabetes, something called hypoglycemia-associated autonomic failure occurs — in English it is called HAAF. Each time there is a low blood sugar episode, the brain adapts to that low level. The next time glucose falls to the same level, the brain already recognizes it as “normal enough” and does not activate the adrenaline alarm. Over time, the threshold at which the alarm activates shifts downward — the body stops producing the warning symptoms at glucose levels where it used to produce them. The patient reaches low glucose levels where the brain is no longer functioning well without having felt any warning symptom.)
Eduardo was quiet for a moment. “¿Y cuándo es peligroso exactamente?” he asked. (And when exactly is it dangerous?)
“El cerebro empieza a funcionar peor — dificultad para pensar con claridad, dificultad para hacer movimientos precisos, confusión — típicamente cuando la glucosa está entre 50 y 55,” Carmen said. “En una persona que siente los síntomas a 70, tiene una ventana de 15 a 20 mg de glucosa para tratar antes de que el cerebro se vea afectado. En una persona que no siente síntomas hasta 50, o que ya no siente síntomas, la glucosa puede bajar a 45 o 40 sin ninguna señal de aviso — y a esas glucosas la persona puede no estar en condiciones de abrir el frigo y sacar el jugo, conducir, o llamar a alguien. Dolores ha visto los episodios porque el sensor alarmó y usted estaba despierto. Un episodio nocturno a esas glucosas — sin sensor, o con el sensor apagado — es otra historia.” (The brain starts to function worse — difficulty thinking clearly, difficulty making precise movements, confusion — typically when glucose is between 50 and 55. In a person who feels symptoms at 70, there is a window of 15 to 20 mg of glucose to treat before the brain is affected. In a person who does not feel symptoms until 50, or who no longer feels symptoms, glucose can fall to 45 or 40 without any warning signal — and at those glucose levels the person may not be able to open the refrigerator and take out juice, drive, or call someone. Dolores has seen the episodes because the sensor alarmed and you were awake. A nocturnal episode at those glucose levels — without a sensor, or with the sensor off — is a different story.)
Dolores had been writing in her notebook. “Entonces ¿tiene solución?” she asked. (So is there a solution?)
“En muchos casos, parcial sí,” Carmen said. “El HAAF es parcialmente reversible si se evita la hipoglucemia por completo durante dos a tres semanas. Si el cerebro no tiene episodios de glucosa baja durante ese tiempo, el umbral al que activa la alarma de adrenalina tiende a volver a subir — no siempre a lo que era antes de los muchos años de diabetes, pero sí lo suficiente como para recuperar algo de la percepción. Lo que vamos a hacer es ajustar los objetivos del sensor para que alarme a 80 en vez de a 70, revisar la dosis basal para reducir el tiempo por debajo de 70, y evitar apilar insulina de corrección. El objetivo de las próximas dos a tres semanas es cero episodios por debajo de 70. Si logramos eso, hay una probabilidad real de que empiece a sentir los síntomas de aviso de nuevo.” (In many cases, partially yes. HAAF is partially reversible if hypoglycemia is avoided completely for two to three weeks. If the brain has no low glucose episodes during that time, the threshold at which it activates the adrenaline alarm tends to shift back upward — not always to what it was before the many years of diabetes, but enough to recover some awareness. What we are going to do is adjust the sensor targets so it alarms at 80 instead of 70, review the basal dose to reduce time below 70, and avoid stacking correction insulin. The goal of the next two to three weeks is zero episodes below 70. If we achieve that, there is a real probability that you will start to feel the warning symptoms again.)
Eduardo absorbed this with the measured attention of someone recalibrating a familiar system. “Treinta y dos años y sigo aprendiendo cosas nuevas sobre la misma enfermedad,” he said. (Thirty-two years and I am still learning new things about the same disease.)
“La diabetes tipo 1 cambia con el tiempo,” Carmen said. “Lo que funcionó durante veinticinco años puede dejar de funcionar igual. Eso no es fracaso — es la biología. Lo importante es que lo captamos ahora y que hay algo específico que se puede hacer.” (Type 1 diabetes changes over time. What worked for twenty-five years may stop working the same way. That is not failure — it is biology. What matters is that we caught it now and there is something specific that can be done.)
Eight practical phrases for type 1 diabetes clinic nurses
- Explaining why type 1 diabetes requires insulin rather than oral agents: “En la diabetes tipo 1, el sistema inmune destruyó las células del páncreas que producen insulina. No hay suficientes células beta propias para mantener la glucosa normal. Los medicamentos orales como la metformina funcionan mejorando la respuesta del cuerpo a la insulina que todavía se produce — pero si ya no hay insulina propia, la metformina no tiene nada sobre qué actuar. La insulina que el paciente se administra reemplaza la hormona que el sistema inmune eliminó.” (In type 1 diabetes, the immune system destroyed the pancreatic cells that produce insulin. There are not enough endogenous beta cells to maintain normal glucose. Oral medications like metformin work by improving the body’s response to the insulin that is still being produced — but if there is no longer endogenous insulin, metformin has nothing to act on. The insulin the patient administers replaces the hormone the immune system eliminated.)
- Explaining what LADA is to a patient diagnosed as type 2 diabetes: “La diabetes tipo 1 de inicio en adultos — llamada LADA — ocurre cuando el sistema inmune comienza a destruir las células del páncreas que hacen insulina, pero de forma más lenta que en niños. Al principio, mientras queda suficiente función del páncreas, puede parecer diabetes tipo 2. Las pruebas de anticuerpos GAD-65 y C-péptido son las que distinguen entre las dos — si los anticuerpos son positivos y el C-péptido es bajo, el mecanismo es autoinmune y el tratamiento correcto es la insulina.” (Adult-onset type 1 diabetes — called LADA — occurs when the immune system begins to destroy the insulin-producing pancreatic cells, but more slowly than in children. At first, while enough pancreatic function remains, it can look like type 2 diabetes. The GAD-65 antibody and C-peptide tests are what distinguish the two — if antibodies are positive and C-peptide is low, the mechanism is autoimmune and the correct treatment is insulin.)
- Explaining the difference between A1c and time-in-range: “La A1c mide el promedio de glucosa de los últimos tres meses. Un promedio puede ser aceptable aunque la glucosa esté muy alta buena parte del tiempo y muy baja otra parte. El sensor de glucosa mide el tiempo dentro del rango objetivo entre 70 y 180 — eso es lo que muestra cuántas horas al día la glucosa está donde debe estar, sin subidas ni bajadas que el promedio esconde.” (The A1c measures the average glucose over the past three months. An average can be acceptable even if glucose is very high part of the time and very low another part. The glucose sensor measures time within the target range between 70 and 180 — that is what shows how many hours per day glucose is where it should be, without the highs and lows that the average hides.)
- Explaining why 70 percent time-in-range is the CGM target: “El objetivo del sensor para la diabetes tipo 1 es estar al menos el 70 por ciento del tiempo dentro del rango 70 a 180 — que son aproximadamente 17 horas al día. Los estudios muestran que ese nivel de tiempo dentro del rango se asocia con menos riesgo de complicaciones en los ojos, los riñones y los nervios con el tiempo. Si el tiempo dentro del rango es menos del 55 por ciento, aunque la A1c parezca aceptable, significa que hay varias horas al día con glucosa alta o baja que representan riesgo real.” (The sensor target for type 1 diabetes is to be at least 70 percent of the time within the range 70 to 180 — which is approximately 17 hours per day. Studies show that this level of time within range is associated with less risk of complications in the eyes, kidneys, and nerves over time. If time within range is less than 55 percent, even if the A1c appears acceptable, it means there are several hours per day with high or low glucose that represent real risk.)
- Explaining hypoglycemia unawareness: “Los síntomas de glucosa baja — el temblor, el sudor, las palpitaciones — los produce la adrenalina del cuerpo como señal de alarma antes de que la glucosa baje tanto que el cerebro funcione mal. Cuando hay muchos episodios de glucosa baja repetidos, el cerebro se adapta y la alarma de adrenalina empieza a sonar más tarde, o deja de sonar. Eso se llama hipoglucemia sin percepción. Que no haya síntomas no significa que la glucosa baja sea segura — significa que la alarma ya no funciona bien y que el paciente puede llegar a una glucosa peligrosa sin aviso.” (The symptoms of low blood sugar — trembling, sweating, palpitations — are produced by the body’s adrenaline as a warning signal before the glucose falls low enough that the brain functions poorly. When there are many repeated low blood sugar episodes, the brain adapts and the adrenaline alarm starts to sound later, or stops sounding. That is called hypoglycemia unawareness. The absence of symptoms does not mean the low glucose is safe — it means the alarm is no longer working well and the patient can reach a dangerous glucose level without warning.)
- Explaining that treating an unfelt low is necessary: “Si el sensor marca glucosa baja pero el paciente no siente nada, hay que tratar igual. El sensor mide la glucosa real — el hecho de que el paciente no sienta síntomas no cambia el número. En alguien con hipoglucemia sin percepción, el cerebro puede estar empezando a funcionar mal justo cuando el paciente dice que se siente bien. Tratar la glucosa baja inmediatamente — aunque no haya síntomas — es lo correcto.” (If the sensor shows low glucose but the patient feels nothing, treatment is still necessary. The sensor measures the actual glucose — the fact that the patient does not feel symptoms does not change the number. In someone with hypoglycemia unawareness, the brain may be starting to function poorly exactly when the patient says they feel fine. Treating the low glucose immediately — even without symptoms — is the right thing.)
- Explaining the treatment for hypoglycemia unawareness: “En muchos casos, si se evitan completamente los episodios de glucosa baja durante dos a tres semanas, la percepción de la hipoglucemia puede mejorar parcialmente. El cerebro necesita ese tiempo sin glucosa baja para restablecer el umbral al que activa la alarma de adrenalina. Eso significa ajustar los objetivos del sensor para que alarme antes, revisar las dosis de insulina, y tratar cada glucosa baja de inmediato. El objetivo es cero episodios por debajo de 70 durante esas semanas.” (In many cases, if low blood sugar episodes are completely avoided for two to three weeks, hypoglycemia awareness can partially improve. The brain needs that time without low glucose to reset the threshold at which it activates the adrenaline alarm. That means adjusting sensor targets to alarm earlier, reviewing insulin doses, and treating every low glucose immediately. The goal is zero episodes below 70 during those weeks.)
- Explaining why the same number of years with diabetes does not mean the same management: “La diabetes tipo 1 cambia con el tiempo. La respuesta del glucagón a la glucosa baja — que ayuda al hígado a liberar glucosa cuando el nivel baja — tiende a disminuir en los primeros años de diabetes tipo 1. La percepción de la hipoglucemia puede cambiar después de muchos años de episodios repetidos. Lo que funcionó durante veinte años puede necesitar ajuste ahora. Eso no significa que el control empeoró — significa que la enfermedad cambió y que el manejo tiene que actualizarse.” (Type 1 diabetes changes over time. The glucagon response to low blood sugar — which helps the liver release glucose when levels fall — tends to diminish in the first years of type 1 diabetes. Hypoglycemia awareness can change after many years of repeated episodes. What worked for twenty years may need adjustment now. That does not mean control got worse — it means the disease changed and management needs to be updated.)
FAQs: type 1 diabetes, Spanish-speaking patients, and type 1 diabetes nursing communication
How do type 1 diabetes clinic nurses explain to a Spanish-speaking patient’s family why adult-onset type 1 diabetes requires insulin instead of the metformin prescribed for type 2 diabetes?
The confusion arises because type 2 and type 1 diabetes share the presentation of elevated blood glucose and the same complication profile, and adult-onset type 1 diabetes (LADA) can be clinically indistinguishable from type 2 diabetes at initial presentation without autoantibody and C-peptide testing. Type 2 diabetes is a disorder of insulin resistance in which the pancreatic beta cells continue to produce insulin but target tissues respond inadequately; metformin acts by activating AMPK in hepatocytes to inhibit gluconeogenesis and reduce hepatic glucose output, a mechanism that depends on the presence of residual insulin secretion. Type 1 diabetes is autoimmune beta-cell destruction: cytotoxic CD8+ T cells and CD4+ T helper cells infiltrate the pancreatic islets and progressively eliminate the insulin-secreting beta cells. In LADA, this destruction proceeds more slowly than in childhood-onset T1D but follows the same mechanism; positive GAD-65 antibodies and low C-peptide confirm the diagnosis. When autoimmune destruction has reduced beta-cell mass to the point where endogenous insulin is insufficient, metformin cannot restore control because the fundamental problem is not that insulin-responsive tissues are resistant to adequate insulin — it is that the insulin the metformin amplification depends on is absent. Insulin replacement is the only treatment that restores what the autoimmune process has destroyed. The Spanish frame: “En la diabetes tipo 1, el sistema inmune destruyó las células que hacen insulina. Metformina amplifica la respuesta a la insulina que queda — pero cuando ya no hay insulina propia que amplificar, solo la insulina inyectada o infundida puede reemplazar lo que se perdió.”
How do type 1 diabetes clinic nurses explain to a Spanish-speaking patient’s family why an A1c near target does not mean glycemic control is adequate when CGM shows low time-in-range?
A1c measures the fraction of hemoglobin molecules that have undergone non-enzymatic glycation proportional to the time-weighted average glucose concentration over the 90–120 day lifespan of circulating red blood cells. This mathematical average obscures variance: a patient spending equal time at 50 and 300 mg/dL has the same A1c as a patient spending all time between 100 and 140, but the clinical reality differs radically. CGM time-in-range (% of readings 70–180 mg/dL) captures daily glucose distribution that A1c obscures. Current ADA/EASD consensus recommends ≥70% TIR for most adults with type 1 diabetes; time above 250 represents direct microvascular glucose toxicity accumulating in retinal capillaries, glomeruli, and nerve fibers; time below 70 represents daily hypoglycemia burden with cognitive, functional, and safety consequences. An A1c of 7.1% with 22% time above 250 and 8% time below 70 indicates a pattern the A1c masks: the apparent adequacy of the average conceals real ongoing microvascular risk and hypoglycemia burden. The Spanish frame: “La A1c es un promedio de tres meses que puede parecer aceptable aunque la glucosa esté muchas horas muy alta o muy baja. El sensor muestra cuánto tiempo al día la glucosa está en el rango correcto. Una A1c de 7 con solo 52 por ciento de tiempo dentro del rango significa 11 horas diarias fuera del rango — el promedio oculta el problema que el sensor revela.”
How do type 1 diabetes clinic nurses explain hypoglycemia unawareness to a Spanish-speaking patient and family who believe that not feeling a low blood sugar means it is not dangerous?
Normal hypoglycemia physiology: as glucose falls below approximately 65–70 mg/dL, hypothalamic glucose sensors activate the sympathoadrenal system, triggering epinephrine release that produces the neurogenic warning symptoms (trembling, sweating, palpitations, anxiety) before neuroglycopenia impairs cognition at approximately 55–60 mg/dL. This sequence allows self-treatment. In long-standing type 1 diabetes, two counter-regulatory defects develop: loss of the glucagon response (which depends on paracrine beta-to-alpha cell signaling within the islet, lost early in T1D); and hypoglycemia-associated autonomic failure (HAAF), in which repeated hypoglycemia shifts the sympathoadrenal activation threshold downward through brain adaptation to frequent low glucose. In HAAF, epinephrine is not released until glucose is lower than previously symptomatic levels, or the epinephrine response is blunted entirely. The patient reaches neuroglycopenic impairment without preceding subjective warning. The absence of symptoms is not safety — it is the failure of the early warning system. Strict hypoglycemia avoidance for 2–3 weeks can partially restore the epinephrine threshold in many patients because the brain adaptation is partly reversible when hypoglycemia stops recurring. The Spanish frame: “Que no haya síntomas cuando la glucosa está baja no significa que la glucosa baja sea segura — significa que la alarma del cuerpo dejó de funcionar bien. El cerebro puede estar funcionando mal justo cuando el paciente dice que se siente bien. Evitar toda glucosa baja durante dos a tres semanas puede restaurar parcialmente la alarma.”
How do type 1 diabetes clinic nurses explain the difference between type 1 and type 2 diabetes to Spanish-speaking patients who assume both are managed similarly?
Type 2 diabetes is a metabolic disorder of progressive insulin resistance and gradual beta-cell secretory decline; the beta cells are present but dysfunctional; management targets insulin sensitivity (metformin, GLP-1 agonists, lifestyle) and incremental insulin supplementation as beta-cell function declines. Type 1 diabetes is autoimmune beta-cell destruction; the beta cells are absent or severely depleted; insulin is not one option among several — it is required from diagnosis for metabolic survival. An untreated person with type 1 diabetes develops DKA within days to weeks from complete insulin deficiency. Advice that applies to early type 2 diabetes (“control with diet and exercise,” “try the oral medication first”) does not apply to type 1 because the mechanisms differ fundamentally. The Spanish frame: “La diabetes tipo 2 tiene insulina propia pero los tejidos no responden bien — los medicamentos mejoran esa respuesta. La diabetes tipo 1 no tiene insulina propia porque el sistema inmune destruyó las células que la hacen — la insulina inyectada o infundida es el único tratamiento posible desde el primer día. No son dos grados de la misma enfermedad — son dos enfermedades distintas que comparten el nombre.”
What are the key Spanish phrases type 1 diabetes clinic nurses use when explaining insulin requirements, CGM targets, and hypoglycemia to Spanish-speaking patients?
Four recurring communication moments where precise language matters. When explaining why insulin is not optional in type 1 diabetes: “La insulina en la diabetes tipo 1 no es el último recurso cuando los otros tratamientos fallan — es el único tratamiento porque no hay células propias que hagan insulina. Sin insulina, la glucosa no puede entrar a las células para producir energía y el cuerpo empieza a quemar grasa de manera que produce ácidos que son tóxicos. La insulina reemplaza la hormona que el sistema inmune eliminó.” (Insulin in type 1 diabetes is not a last resort when other treatments fail — it is the only treatment because there are no endogenous cells to make insulin. Without insulin, glucose cannot enter the cells to produce energy and the body begins to burn fat in a way that produces toxic acids. Insulin replaces the hormone the immune system eliminated.) When explaining why A1c alone is insufficient: “La A1c de 7 puede resultar de glucosa estable y bien controlada, o puede resultar de pasar mucho tiempo entre 50 y 300 — el promedio de los dos extremos puede ser igual al promedio del control bueno. El sensor de glucosa continuo muestra el tiempo real dentro del rango objetivo y hace visible lo que el promedio esconde.” (An A1c of 7 can result from stable, well-controlled glucose, or it can result from spending much time between 50 and 300 — the average of the two extremes can equal the average of good control. The continuous glucose sensor shows the actual time within the target range and makes visible what the average hides.) When explaining the 70 percent TIR target: “El objetivo del sensor es al menos 70 por ciento del tiempo entre 70 y 180 — aproximadamente 17 horas al día. Menos del 55 por ciento de tiempo dentro del rango, aunque la A1c esté cerca de 7, significa varias horas diarias de glucosa alta o baja que representan riesgo de complicaciones y calidad de vida reducida.” (The sensor target is at least 70 percent of time between 70 and 180 — approximately 17 hours per day. Less than 55 percent of time within range, even if the A1c is near 7, means several daily hours of high or low glucose representing complication risk and reduced quality of life.) When explaining hypoglycemia unawareness treatment: “Para intentar recuperar la percepción de la glucosa baja, hay que evitar completamente los episodios de glucosa baja durante dos a tres semanas — subir el objetivo del sensor, revisar la insulina basal para reducir los bajos nocturnos, y tratar inmediatamente cualquier alarma de bajo aunque no haya síntomas. El cerebro necesita ese tiempo sin glucosa baja para restablecer la alarma de adrenalina.” (To try to recover hypoglycemia awareness, low blood sugar episodes must be completely avoided for two to three weeks — raise the sensor target, review the basal insulin to reduce nighttime lows, and immediately treat any low alarm even without symptoms. The brain needs that time without low blood sugar to reset the adrenaline alarm.)